Expression of secretagogin in clear-cell renal cell carcinomas is associated with a high metastasis rate

Human Pathology

Volumn 42, Issue 5, 2011, Pages 641-648

  Ilhan, Aysegül ^a   Neziri, Dashurie ^a   Maj, Magdalena ^a   Mazal, Peter R ^a   Susani, Martin ^a   Base, Wolfgang ^a   Gartner, Wolfgang ^a,b   Wagner, Ludwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b St Vincent Hospital   (Austria)

Author keywords

Chromophobe carcinoma; Clear cell renal cell carcinoma; Oncocytoma; Papillary renal cell carcinoma; Secretagogin

Indexed keywords

CALCIUM BINDING PROTEIN; SECRETAGOGIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLEAR CELL RENAL CELL CARCINOMA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; ONCOCYTOMA; PROTEIN EXPRESSION;

ADENOMA, OXYPHILIC; AGED; CALCIUM-BINDING PROTEINS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED;

EID: 79954578060     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.10.004     Document Type: Article

References (37)

1. Jemal A., Siegel R., and Ward E. Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96 (Pubitemid 351521864)
2. Curti B.D. Renal cell carcinoma Jama 292 2004 97 100 (Pubitemid 38923800)
3. McDermott D.F. Immunotherapy of metastatic renal cell carcinoma Cancer 115 2009 2298 2305
4. McDermott D.F. The application of high-dose interleukin-2 for metastatic renal cell carcinoma Med Oncol 26 Suppl 1 2009 13 17
5. Saylor P.J., and Michaelson M.D. New treatments for renal cell carcinoma: targeted therapies J Natl Compr Canc Netw 7 2009 645 656
6. Heng D.Y., and Bukowski R.M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma Curr Cancer Drug Targets 8 2008 676 682
7. Rekha P.R., Rajendiran S., Rao S., Shroff S., Joseph L.D., and Prathiba D. Histological reclassification, histochemical characterization and c-kit immunoexpression in renal cell carcinoma Indian J Urol 24 2008 343 347
8. Skinnider B.F., and Amin M.B. An immunohistochemical approach to the differential diagnosis of renal tumors Semin Diagn Pathol 22 2005 51 68 (Pubitemid 43163179)
9. Zhou M., Roma A., and Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms Clin Lab Med 25 2005 247 257 (Pubitemid 40545818)
10. Adley B.P., Papavero V., Sugimura J., Teh B.T., and Yang X.J. Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma Anal Quant Cytol Histol 28 2006 228 236 (Pubitemid 44162599)
11. Abrahams N.A., MacLennan G.T., and Khoury J.D. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray Histopathology 45 2004 593 602 (Pubitemid 40029819)
12. Rocca P.C., Brunelli M., and Gobbo S. Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study Mod Pathol 20 2007 722 728 (Pubitemid 46933453)
13. Capozzi F., Casadei F., and Luchinat C. EF-hand protein dynamics and evolution of calcium signal transduction: an NMR view J Biol Inorg Chem 11 2006 949 962 (Pubitemid 44786385)
14. 2+-binding protein J Biol Chem 275 2000 24740 24751 (Pubitemid 30626577)
15. Birkenkamp-Demtroder K., Wagner L., and Brandt Sorensen F. Secretagogin is a novel marker for neuroendocrine differentiation Neuroendocrinology 82 2005 121 138
16. Gartner W., Lang W., Leutmetzer F., Domanovits H., Waldhausl W., and Wagner L. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein Cereb Cortex 11 2001 1161 1169 (Pubitemid 33108243)
17. 2+-binding protein specifying subpopulations of telencephalic neurons Proc Natl Acad Sci U S A 106 2009 22492 22497
18. Pipp I., Wagner L., Rossler K., Budka H., and Preusser M. Secretagogin expression in tumours of the human brain and its coverings Apmis 115 2007 319 326 (Pubitemid 46743945)
19. Xing X., Lai M., and Gartner W. Identification of differentially expressed proteins in colorectal cancer by proteomics: down-regulation of secretagogin Proteomics 6 2006 2916 2923
20. Gartner W., Vila G., and Daneva T. New functional aspects of the neuroendocrine marker secretagogin based on the characterization of its rat homolog Am J Physiol Endocrinol Metab 293 2007 E347 354
21. Adolf K., Wagner L., and Bergh A. Secretagogin is a new neuroendocrine marker in the human prostate Prostate 67 2007 472 484 (Pubitemid 46536941)
22. Mazal P.R., Exner M., and Haitel A. Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma Hum Pathol 36 2005 22 28 (Pubitemid 40215630)
23. Storkel S., Eble J.N., and Adlakha K. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) Cancer 80 1997 987 989
24. Eble J.N., Sauter G., and Epstein J.I. World Health Organization classification of tumors: tumours of the urinary system and male genital organs 2004 IARC Press 9 43
25. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma Am J Surg Pathol 6 1982 655 663 (Pubitemid 13234762)
26. Lenburg M.E., Liou L.S., Gerry N.P., Frampton G.M., Cohen H.T., and Christman M.F. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data BMC Cancer 3 2003 31
27. Martignoni G., Pea M., and Chilosi M. Parvalbumin is constantly expressed in chromophobe renal carcinoma Mod Pathol 14 2001 760 767 (Pubitemid 33069834)
28. Kim DS, Choi YP, Kang S, et al. Panel of candidate wbiomarkers for renal cell carcinoma. J Proteome Res.
29. Zierhut B., Daneva T., and Gartner W. Setagin and secretagogin-R22: posttranscriptional modification products of the secretagogin gene Biochem Biophys Res Commun 329 2005 1193 1199 (Pubitemid 40568697)
30. Petersson S., Bylander A., Yhr M., and Enerback C. S100A7 (Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells BMC Cancer 7 2007 205
31. Carlsson H., Petersson S., and Enerback C. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development Int J Oncol 27 2005 1473 1481
32. Jiang W.G., Watkins G., Douglas-Jones A., and Mansel R.E. Psoriasin is aberrantly expressed in human breast cancer and is related to clinical outcomes Int J Oncol 25 2004 81 85
33. 2+ sensor J Biol Chem 277 2002 16662 16672 (Pubitemid 34967685)
34. 2+-binding properties of human recombinant calretinin-22k and calretinin J Biol Chem 272 1997 29663 29671
35. Edmonds B., Reyes R., Schwaller B., and Roberts W.M. Calretinin modifies presynaptic calcium signaling in frog saccular hair cells Nat Neurosci 3 2000 786 790 (Pubitemid 30485703)
36. Attems J., Preusser M., Grosinger-Quass M., Wagner L., Lintner F., and Jellinger K. Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease Neuropathol Appl Neurobiol 34 2008 23 32
37. Maj M, Gartner W, Ilhan A, Neziri D, Attems J, Wagner L. Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. J Endocrinol 205:25-36